

Phase 1, 2 and 3 clinical trials (studies) of new medicines

Project code: TACL3-0561660: 2024 - 2025

GlaxoSmithKline is implementing a research project in Greece with a total budget of EUR 2,883,247.22, strengthening the country's contribution to the European research and development ecosystem in the pharmaceutical sector. The project generates added value for both the economy and the healthcare system, supports employment, leverages the country's highly skilled scientific talent, and contributes to expanding patient access to modern therapeutic options.

The process of bringing new medicine from the research laboratory to the market requires ensuring patient safety and the medicine's efficacy. This is achieved through the conduct of the required clinical trials, in which individuals voluntarily receive the medicine and are monitored for its effects.

In this context, GlaxoSmithKline, through its sustained investment in Research and Development, is conducting Phase 1, 2 and 3 clinical trials in Greece, with the aim of generating the necessary data to support the marketing authorization of new medicinal products. These studies cover important therapeutic areas and follow a staged research process that ensures the safety and efficacy of the medicines under evaluation, in line with applicable scientific and regulatory standards.

The research project is implemented under the action "Reform of the clawback system and offsetting it against research and investment expenditure" for the years 2024–2025, **within the framework of the National Recovery and Resilience Plan "Greece 2.0", funded by the European Union – NextGenerationEU.**



**Funded by the
European Union**
NextGenerationEU